FDA Updates Atazanavir Sulfate Capsule Labeling

“Recently [February 4, 2013] FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes. “Section 5 Warnings and Precautions was revised to include cholelithiasis ...   “In section 6 Adverse Reactions: Postmarketing Experience, interstitial nephritis was added. “In section 7 Drug Interactions: information regarding coadministration with boceprevir, carbamazepine, phenytoin, phenobarbital, lamotrigine and voriconazole was added.” The updated labeling will be available at the FDA website. More information is available: FDA: Press release AIDSinfo: Atazanavir (Reyataz) patient drug summary